

**THE**  
**TBE**  
**BOOK** **FIFTH EDITION**

Prof. Dr. Gerhard Dobler  
Dr. Wilhelm Erber  
Dr. Michael Bröker  
Prof. Dr. Heinz-Josef Schmitt

**GLOBAL**  
**HEALTH**  
**PRESS**

Published by  
Global Health Press Pte Ltd  
3 Kallang Way 2A  
#04-03 Fong Tat Building  
Singapore 347493

<https://id-ea.org/tbe/>

<https://TBNews.com>

**The TBE Book (5th Edition)**

Copyright © Global Health Press Pte Ltd, 2022

All rights reserved. Without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, scanning, or otherwise), without the prior written permission of both the copyright owners and publisher of this book.

The greatest care has been taken in compiling this book. However, no responsibility can be accepted by the publisher or compilers for the accuracy of the information presented.

Where opinion is expressed it is that of the author and does not necessarily coincide with the editorial views of Global Health Press.

While every effort has been made to contact copyright-holders of material produced or cited in this book, in the case of those it has not been possible to contact successfully, the editors, authors, and the publisher will be glad to make amendments in further editions.

Publication of this book was funded by Pfizer Inc.

ISSN: 2661-3980

# In memory of

## Christian Kunz

1927 – 2020



**Father of the first TBE vaccine**

Considered a pioneer of virology in Austria, Christian Kunz's interest in scientific research awoke in the 1950s and was supported by study visits to the then German strongholds for virology - Freiburg, Tübingen and Marburg.

His early publications received international attention and earned him a grant from the Rockefeller Foundation to continue his research at Rockefeller Laboratories in New York.

The experiences at research institutes and contacts with outstanding international scientists significantly shaped his further career.

Back in Vienna, he established the Institute of Virology with a research focus on arthropod-borne diseases and especially TBE, the by far most common virus-related disease of the central nervous system in endemic areas.

He was intensively engaged in virus diagnostics, basic medical virology, and the life cycle of the TBE virus in nature. Also, TBE-endemic areas throughout Austria were identified. He finally used all his knowledge to develop a highly effective vaccine against TBE, initially in cooperation with an English research institute and later with the Austrian pharmaceutical company IMMUNO.

The vaccine was first licensed in 1976 and ever since, the broad use of the vaccine in Austria has led to an impressive reduction of the TBE burden of disease.

Prof. Kunz was a founding member and for many years Chairman of the "European Group for Rapid Virus Diagnosis," which became the "European Society for Clinical Virology" in 1997, an association of leading medical virologists from across Europe, who focused primarily on the development of new methods for early detection of viral infections.

He was awarded the Loeffler-Frosch-Medal of the International Society of Virology for his outstanding achievements for the development of Virology in German-speaking countries.

We deeply appreciate Christian Kunz's scientific achievements, and the editors and publisher dedicate this 3rd Edition of "The TBE Book" (2020) to him in commemoration.

Franz X. Heinz,  
Center for Virology,  
Medical University of Vienna

# Contents

<b>List of Contributing Authors</b>	1
<b>Introduction</b>	7
Gerhard Dobler, Wilhelm Erber, Michael Bröker and Heinz-Josef Schmitt - Editors	
<b>Chapter 1: A short history of TBE</b>	11
Olaf Kahl, Vanda V. Pogodina <sup>†</sup> , Tatjana Poponnikova, Jochen Süss and Vladimir I. Zlobin	
<b>Chapter 2a: TBE-Virology</b>	17
Daniel Růžek, Kentaro Yoshii, Marshall E. Bloom and Ernest A. Gould	
<b>Chapter 2b: The molecular and antigenic structure of the TBEV</b>	33
Franz-Xaver Heinz and Karin Stiasny	
<b>Chapter 3: Transmission / natural cycle</b>	48
Lidia Chitimia-Dobler, Ute Mackenstedt and Olaf Kahl	
<b>Chapter 4: Pathogenesis of TBE with a focus on molecular mechanisms</b>	65
Andrea Kröger and Anna K. Överby	
<b>Chapter 5: TBE in adults</b>	78
Johannes P. Borde and Joanna Zajkowska	
<b>Chapter 6: TBE in children</b>	93
Mikael Sundin and Malin Veje	
<b>Chapter 7: TBE in special clinical situations</b>	99
Gerhard Dobler and Igor Stoma	
<b>Chapter 8: TBE in animals</b>	106
Martin Pfeffer, Hannah M. Schmuck and Michael Leschnik	
<b>Chapter 9: Immunology of TBEV infection</b>	120
Sara Gredmark-Russ and Renata Varnaite	
<b>Chapter 10: Diagnosis</b>	134
Gerhard Dobler	
<b>Chapter 11: General epidemiology of TBE</b>	142
Gerhard Dobler and Sergey Tkachev	
<b>Chapter 12a: TBE-epidemiology by country – an overview</b>	155
Wilhelm Erber, Heinz-Josef Schmitt and Tamara Vuković-Janković	
<b>Chapter 12b: TBE by country – country data</b>	173

• <b>Austria:</b> Karin Stiasny, Heidemarie Holzmann, Isabel Santonja and Franz-Xaver Heinz	174
• <b>Belarus:</b> Volha Kniazeva, Wilhelm Erber and Tamara Vuković-Janković	178
• <b>Belgium:</b> Marjan Van Esbroeck, Tinne Lernout, Vanessa Suin and Steven Van Gucht	183
• <b>Bosnia and Herzegovina:</b> Wilhelm Erber and Tamara Vuković-Janković	186
• <b>Bulgaria:</b> Iva Christova	188
• <b>China:</b> Yang Junfeng and Heinz-Josef Schmitt	191
• <b>Croatia:</b> Wilhelm Erber and Tamara Vuković-Janković	196
• <b>Czech Republic:</b> Petr Pazdiora	199
• <b>Denmark:</b> Anders Fomsgaard	203
• <b>Estonia:</b> Kuulo Kutsar	207
• <b>Finland:</b> Anu Jääskeläinen and Heidi Åhman	215
• <b>France:</b> Yves Hansmann and Aurélie Velay	220
• <b>Germany:</b> Gerhard Dobler and Ute Mackenstedt	226
• <b>Hungary:</b> Anna Nagy, Ferenc Schneider, Eszter Mezei and András Lakos	231
• <b>Italy:</b> Valentina Tagliapietra, Flavia Riccardo, Martina Del Manso and Giovanni Rezza	237
• <b>Japan:</b> Kentaro Yoshii	244
• <b>Kazakhstan:</b> Andrey Dmitrovskiy	247
• <b>Kyrgyzstan:</b> Wilhelm Erber	254
• <b>Latvia:</b> Dace Zavadska and Zane Freimane	255
• <b>Lithuania:</b> Auksė Mickienė	263
• <b>Moldova:</b> Wilhelm Erber and Tamara Vuković-Janković	268
• <b>Mongolia:</b> Tserenrorov Damdindorj, Uyanga Baasandagva, Uranshagai Narankhuu, Tsogbadrakh Nyamdorj, Burmaajav Badrakh and Burmaa Khoroljav	269
• <b>Netherlands:</b> Johannes H. J. Reimerink, Hein Sprong, Margriet Harms and Chantal B.E.M. Reusken	274
• <b>Norway:</b> Katrine M. Paulsen, Rose Vikse, Arnulf Soleng, Kristin S. Edgar, Heidi E.H. Lindstedt, Dagny C.H. Dorenberg, Berit Sofie Wiklund and Åshild K. Andreassen	279
• <b>Poland:</b> Katarzyna Pancer and Włodzimierz Gut	289
• <b>Romania:</b> Lidia Chitimia-Dobler, Adriana Hristea, Wilhelm Erber and Tamara Vuković-Janković	296
• <b>Russia:</b> Vladimir I. Zlobin, Maria Esyunina and Maria Syrochkina	300
• <b>Serbia:</b> Vladimir Petrović, Elizabeta Ristanović and Aleksandar Potkonjak	312
• <b>Slovakia:</b> Jana Kerlik	316
• <b>Slovenia:</b> Zoran Simonović and Tamara Vuković-Janković	327
• <b>South Korea:</b> Song Joon Young	334
• <b>Sweden:</b> Åke Lundkvist	337
• <b>Switzerland and Liechtenstein:</b> Daniel Desgrandchamps and Klara M. Pósfay-Barbe	344
• <b>Tunisa:</b> Elyes Zhioua	350
• <b>Ukraine:</b> Igor Nebogatkin, Olga Onishchuk, Oleksandr Hnatiuk, Wilhelm Erber and Tamara Vuković-Janković	351
• <b>United Kingdom:</b> Maya Holding, Heinz-Josef Schmitt and Gillian Ellsbury	356

<b>Chapter 12c: Global distribution of the TBEV</b>	361
Gerhard Dobler, Wilhelm Erber and Heinz-Josef Schmitt	

<b>Chapter 13: TBE as a matter of public health</b>	362
Michael Kunze, Wilhelm Erber and Martin Haditsch	

<b>Chapter 14: TBE-prevention: vaccines and immunoglobulins</b>	370
Eva Maria Pöllabauer and Herwig Kollaritsch	

## List of contributing authors

*(in alphabetical order)*

**Dr. Heidi Åhman,**

Senior Manager Medical Lead Finland & Baltics, Pfizer Vaccines, Helsinki, Finland

**Prof. Dr. Åshild Andreassen,**

Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**Dr. Uyanga Baasandagva,**

Epidemiologist, National Center for Zoonotic Diseases, Ulaanbaatar, Mongolia

**Prof. Dr. Burmaajav Badrakh,**

Scientific Secretary of the Mongolian Academy of Medical Sciences and Head of Public Health Department of "Ach" Medical University, Ulaanbaatar, Mongolia

**Dr. Marshall E. Bloom,**

National Institutes of Health, Laboratory of Virology, Rocky Mountain Laboratories, Hamilton, MT, USA

**Priv.-Doz. Dr. Johannes P. Borde,**

Praxis Dr. J. Borde, Gesundheitszentrum Oberkirch, Germany

Department of Medicine II, Division of Infectious Diseases, Medical Center – University of Freiburg, Germany

**Dr. Michael Bröker,**

Editor, Global Health Press, Singapore / Marburg, Germany

**Dr. Lidia Chitimia-Dobler,**

Bundeswehr Institute of Microbiology, Munich, Germany

**Prof. Dr. Iva Christova,**

Department of Microbiology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria

**Dr. Tserennorov Damdindorj,**

Scientific secretary in National Center for Zoonotic Diseases, Ulaanbaatar, Mongolia

**Dr. Martina Del Manso,**

Department of Infectious Diseases, Istituto Superiore di Sanità, Roma, Italy

**Dr. med. Daniel Desgrandchamps,**

Pediatric Infectious Diseases, Scientific Consulting Daniel Desgrandchamps, Rotkreuz, Switzerland

**Prof. Andrey Dmitrovskiy,**

National Scientific Center for Extremely Dangerous Infections, Almaty, Kazakhstan

**Prof. Dr. Gerhard Dobler,**

Bundeswehr Institute of Microbiology, Munich, Germany

**Dr. Dagny Cathrine Haug Dorenberg,**

Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**B.Sc. Kristin Skarsfjord Edgar,**

Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**Dr. Gillian Ellsbury,**

Medical Director, Vaccines UK & Ireland, Pfizer Vaccines, Tadworth, United Kingdom

**Dr. Wilhelm Erber,**

Director Medical and Scientific Affairs, Pfizer Vaccines, Vienna, Austria

**Dr. Maria Sergeevna Esyunina,**

Regional Medical Advisor, Vaccines, Pfizer Innovations LLC, Moscow, Russia

**Dr. Anders Fomsgaard,**

Virus R&D Laboratory, Statens Serum Institute, Copenhagen, Denmark  
Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark

**Dr. Zane Freimane,**

Riga Stradins University, Riga, Latvia

**Dr. Ernest A. Gould,**

Aix-Marseille Université, Marseille, France

**Dr. Sara Gredmark-Russ,**

Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

**Prof. Dr. Włodzimierz Gut,**

Department of Virology, National Institute of Public Health-NIH (NIPH-NIH), Warsaw, Poland

**Prof. Dr. Dr. Martin Haditsch,**

Medical Head, Labor Hannover MVZ, Hannover, Germany; TravelMedCenter Leonding, Austria

**Dr. Yves Hansmann,**

Infectious Disease Department, Strasbourg University Hospital, Strasbourg, France

**M.Sc. Margriet Harms,**

National Institute for Public Health and the Environment, Bilthoven, the Netherlands

**Prof. Dr. Franz-Xaver Heinz,**

Center for Virology, Medical University of Vienna, Austria

**Oleksandr Hnatiuk**

Epidemiologist, SI Volyn Regional Laboratory Center of the Ministry of Health of Ukraine, Kiev, Ukraine

**Dr. Maya Holding,**

Virology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, United Kingdom  
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, United Kingdom

**Prof. Dr. Heidemarie Holzmann,**

Center for Virology, Medical University of Vienna, Austria

**Ass. Prof. Adriana Hristea,**

National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania

**Dr. Anu Jääskeläinen,**

Department of Virology, Medicum, University of Helsinki, Helsinki, Finland  
Helsinki University Hospital, Laboratory Services (HUSLAB), Department of Clinical Microbiology, Helsinki, Finland

**Dr. Olaf Kahl,**  
tick-radar GmbH, Berlin, Germany

**Dr. Jana Kerlik,**  
Department of Epidemiology, Regional Public Health Authority in Banská Bystrica, Slovakia

**Dr. Burmaa Khoroljav,**  
Department of Epidemiology, National Center for Zoonotic Disease, Ulaanbaatar, Mongolia

**Dr. Volha Kniazeva,**  
Republican Research and Practical Center for Epidemiology and Microbiology. Minsk, Belarus

**Prof. Dr. Herwig Kollaritsch,**  
Institute for Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria

**Prof. Dr. Andrea Kröger,**  
Institute of Medical Microbiology, Otto-von-Guericke-University, Magdeburg, Germany

**Prof. Dr. Michael Kunze,**  
Center for Public Health, Institute of Social Medicine, Medical University Vienna, Austria

**Dr. Kuulo Kutsar,**  
Health Board, Tallinn, Estonia

**Dr. András Lakos,**  
Centre for Tick-borne Diseases, Outpatient Service, Budapest, Hungary

**Dr. Tinne Lernout,**  
Epidemiology of Infectious Diseases, Epidemiology and Public Health Directorate, Sciensano, Brussels, Belgium

**Priv.-Doz. Dr. Michael Leschnik,**  
Clinical Unit of Internal Medicine Small Animals, Department and Clinic of Companion Animals and Horses,  
University of Veterinary Medicine Vienna, Austria

**Heidi Elisabeth H. Lindstedt,**  
Senior Adviser, Norwegian Institute of Public Health, Division of Infection Control and Environmental Health, Oslo, Norway

**Prof. Dr. Åke Lundkvist,**  
Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden

**Prof. Dr. Ute Mackenstedt,**  
Department of Parasitology, University of Hohenheim, Stuttgart, Germany

**MScPH Eszter Mezei,**  
National Public Health Center, Department of Epidemiology and Infection Control, Budapest, Hungary

**Prof. Dr. Auksė Mickienė,**  
Department of Infectious Diseases, Medical Academy of the Lithuanian University of Health Sciences, Kaunas, Lithuania

**Dr. Anna Nagy,**  
National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary

**Dr. Uranshagai Narankhuu,**  
Department of Epidemiology, National Center for Zoonotic Disease, Ulaanbaatar, Mongolia



**Dr. Igor Nebogatkin,**

I.I. Schmalhausen Institute of Zoology of the National Academy of Sciences of Ukraine (NASU), Kiev, Ukraine  
SI Public Health Centre of the Ministry of Healthcare of Ukraine, Kiev, Ukraine

**Dr. Tsogbadrakh Nyamdorj,**

Director, National Center for Zoonotic Diseases, Ulaanbaatar, Mongolia

**Assoc. Prof. Dr. Anna K. Överby,**

Department of Clinical Microbiology, Virology, Umeå University, Sweden  
The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå, Sweden

**Olga Onishchuk,**

Epidemiologist, Manevychi interdistrict department of the SI Volyn Regional Laboratory Center of the Ministry of Health of Ukraine, Kiev, Ukraine

**Dr. Katarzyna Pancer,**

Department of Virology, National Institute of Public Health-NIH (NIPH-NIH), Warsaw, Poland

**Dr. Katrine M. Paulsen,**

Senior Adviser Microbiology, Tine SA, Oslo, Norway

**Prof. Dr. Petr Pazdiora,**

Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

**Prof. Dr. Vladimir Petrović,**

Institute of Public Health of Vojvodina, Novi Sad, Serbia

**Prof. Dr. Martin Pfeffer,**

Institute of Animal Hygiene and Veterinary Public Health, Center for Veterinary Public Health, Faculty of Veterinary Medicine, University of Leipzig, Germany

**Dr. Eva-Maria Pöllabauer,**

Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria

**Prof. Vanda Vatslavovna Pogodina<sup>†</sup>,**

Ministry of Science and Higher Education of the Russian Federation, Moscow, Russia  
Federal State Budgetary Scientific Institution, Moscow, Russia  
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia (*† passed away in early 2020*)

**Prof. Tatjana Poponnikova,**

Department of Neurology, Neurosurgery and Medical Genetics, Kemerovo State Medical University, Russian Federation

**Prof. Dr. Klara M. Pósfay-Barbe,**

Department of Pediatrics, Children's Hospital of Geneva, University Hospitals of Geneva, Switzerland

**Prof. Dr. Aleksandar Potkonjak,**

Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad, Serbia

**Bsc. Johannes Hermanus Jozef Reimerink,**

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

**Dr. Chantal B.E.M. Reusken,**

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

**Dr. Giovanni Rezza,**

Department of Infectious Diseases, Istituto Superiore di Sanità, Roma, Italy

**Dr. Flavia Riccardo,**

Department of Infectious Diseases, Istituto Superiore di Sanità, Roma, Italy

**Prof. Dr. Elizabeta Ristanović,**

Military Medical Academy, Belgrade, Serbia

**Assoc. Prof. Dr. Daniel Růžek,**

Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, České Budějovice, Czech Republic  
Veterinary Research Institute, Brno, Czech Republic

**Dr. Isabel Santonja**

Center for Virology, Medical University of Vienna, Austria

**Prof. Dr. Heinz-Josef Schmitt,**

Vice President, Global Lead Viral Vaccines and Clinical Affairs, Pfizer Vaccines, Collegeville, PA, USA  
Johannes Gutenberg University, Mainz, Germany

**Ph.D.-student Hannah M. Schmuck,**

Institute of Animal Hygiene and Veterinary Public Health, Center for Veterinary Public Health, Faculty of Veterinary Medicine,  
University of Leipzig, Germany

**Dr. Ferenc Schneider,**

Department of Infectious Diseases, Markusovszky Teaching Hospital, Szombathely, Hungary

**Dr. Zoran Simonović,**

National Institute of Public Health, Maribor, Slovenia

**Dr. Arnulf Soleng,**

Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**Prof. Song Joon Young,**

Korea University College of Medicine, Seoul, South Korea

**Dr. Hein Sprong,**

National Institute for Public Health and the Environment, Bilthoven, the Netherlands

**Prof. Dr. Karin Stiasny,**

Center for Virology, Medical University of Vienna, Austria

**Dr. Igor Stoma,**

Belarusian State Medical University, Minsk, Belarus

**Dr. Vanessa Suin,**

Viral Diseases, Infectious diseases in humans directorate, Sciensano, Brussels, Belgium

**Dr. Mikael Sundin,**

Division of Paediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden  
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

**Prof. Dr. Jochen Süß,**

Tick Information Center, Lippersdorf, Germany

**Dr. Maria Syrochkina,**  
Pfizer Vaccines, Moscow, Russia

**Dr. Valentina Tagliapietra,**  
Research and Innovation Centre, Fondazione Edmund Mach, San Michele all'Adige, Italy

**Dr. Sergey E. Tkachev,**  
Research Center "Regulatory Genomics" of Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia  
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia

**Dr. Marjan Van Esbroeck,**  
National Reference Center for Arboviruses, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

**Dr. Steven Van Gucht,**  
Viral Diseases, Infectious Diseases in Humans Directorate, Sciensano, Brussels, Belgium

**M.Sci. Renata Varnaite,**  
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

**Dr. Malin Veje,**  
Department of Infectious Diseases, University of Gothenburg, Sweden

**Dr. Aurélie Velay,**  
Institute of Virology, Strasbourg University Hospital, Strasbourg, France

**Dr. Rose Vikse,**  
Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**Dr. Tamara Vuković-Janković,**  
Senior Medical Manager, Medical and Scientific Affairs, International Developed Markets Pfizer, Belgrade, Serbia

**Mpharm Berit Sofie Wiklund,**  
Norwegian Institute of Public Health, Division for Infection Control and Environmental Health, Oslo, Norway

**Dr. Yang Junfeng,**  
Medical Affairs, Pfizer Investment Co., Ltd., Beijing, China

**Dr. Kentaro Yoshii,**  
Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan

**Prof. Dr. Joanna Zajkowska,**  
Department of Infectious Diseases and Neuroinfections, Medical University in Białystok, Poland

**Assoc. Prof. Dace Zavadskā,**  
Department of Paediatrics, Riga Stradins University, Riga, Latvia  
Department of Children Infectious Diseases, Children Clinical University Hospital, Riga, Latvia

**Prof. Elyes Zhioua,**  
Department of Parasitology, Institute Pasteur of Tunisia, Tunis, Tunisia

**Prof. Vladimir Igorevich Zlobin,**  
Irkutsk State Medical University, Ministry of Public Health of Russian Federation, Irkutsk, Russian Federation

## General epidemiology of TBE

Gerhard Dobler and Sergey Tkachev

### Key Points

- Tick-borne encephalitis virus (TBEV) exists in natural foci, which are areas where TBEV is circulating among its vectors (ticks of different species and genera) and reservoir hosts (usually rodents and small mammals).
- Based on phylogenetic studies, four TBEV subtypes (Far-Eastern, Siberian, European, Baikalian) and two putative subtypes (Himalayan and “178-79” group) are known. Within each subtype, some genetic lineages are described.
- The European subtype (TBEV-EU) (formerly known also as the “Western subtype”) of TBEV is prevalent in Europe, but it was also isolated in Western and Eastern Siberia in Russia and South Korea.
- The Far-Eastern subtype (TBEV-FE) was preferably found in the territory of the far-eastern part of Eurasia, but some strains were isolated in other regions of Eurasia.
- The Siberian (TBEV-SIB) subtype is the most common and has been found in almost all TBEV habitat areas.
- The Baikalian subtype is prevalent around Lake Baikal and was isolated several times from ticks and rodents.
- In addition to the four TBEV subtypes, one single isolate of TBEV (178-79) and two genetic sequences (Himalayan) supposed to be new TBEV subtypes were described in Eastern Siberia and China.
- The data on TBEV seroprevalence in humans and animals can serve as an indication for the presence or absence of TBEV in studied area.

### The natural focus


In the early 1920s, reports surfaced concerning a severe form of brain disease in woodcutters, topographers, road construction workers, and residents of newly founded villages in the Taiga forest in the far eastern region of the former Soviet Union. The severity of the disease was such that in 1937 an expedition was organized to detect the origin of this unusual disease. During this first Taiga expedition to identify the etiology of a newly occurring form of encephalitis, Zil’ber et al.<sup>1</sup> showed that the etiologic agent of this disease seemed to be a filterable pathogen that was transmitted by ticks of the genera *Ixodes* and *Dermacentor*. In at least 2 more expeditions to study the transmission of this disease (later named Russian Spring Summer Encephalitis, and currently known as tick-borne encephalitis [TBE]) Pavlovsky recognized that it was associated with specific types of landscape, and from this observation he developed his theory on the nature of human diseases.<sup>2</sup>

In his theory, Pavlovsky describes a natural focus (“Nidus”) of a disease as an area where specific climate, vegetation, soil, and favorable microclimatic conditions exist, so that vectors, donors, and recipients of infection find favorable conditions to exist. In this respect a natural focus of disease is related to a specific geographical landscape. According to

this theory, humans acquire a zoonosis with natural foci only if they are in the territory of the natural focus in a definite season of the year and if they are attacked as prey by hungry vectors or come into contact with the animal reservoir (via hunting), which have already acquired the infection as carriers or donors of the respective agent.

During the last century a number of scientists, especially from Russia and the Czech Republic, studied in detail the landscapes that are associated with the occurrence of TBE. Rosicky<sup>3</sup> and Blaskovic<sup>4</sup> defined landscape types of TBE natural foci (Fig. 1).

**Figure 1:** Different landscape types of TBE natural foci (according to Rosicky<sup>3</sup> and Blaskovic et al.<sup>4</sup>)



According to this classification, a theriodic focus is a focus in a forest with game animals as the main vertebrate hosts for adult ticks. A boskematic focus is a focus where meadows dominate and where farm animals are the main vertebrate hosts for adult tick stages. The theriodic-boskematic form is a mix of the two, having both types of landscape.

Another classification was made by Blaskovic et al.,<sup>4</sup> who categorized the natural foci according to their main geographic location into Hercynian foci (located mainly in the Central German Uplands), Carpathian foci (located in the far southeastern part of Europe), and Pannonian foci (located at the western part of the Hungarian Danube lowlands). Similarly, Korenberg et al.<sup>5</sup> made a classification according to the main geographic type (and not so much landscape type) for the TBE foci in Eurasia (Fig. 2).

By these classifications, the European TBE foci are located in the Central European–Mediterranean TBE focus region according to Korenberg et al.<sup>5</sup> The classification developed by Rosicky<sup>3</sup> indicates the European TBE foci are mainly of the theriodic type, while Eastern European countries have the mixed type or rarely also the boskematic type. Overall, these classifications may be helpful in getting an impression of the focus type in the landscape, but they are not very helpful for describing a TBE natural focus in detail. Also, so far, no clear associations have been identified between genetic profiles or phenotypic characteristics of TBEV strains and their respective focus types.

## The natural cycle

As described above, a natural focus is an area where the ecological conditions allow the presence and transmission of a pathogen. In the case of TBEV, a natural focus is an area where TBEV is circulating among its vectors (ticks of different species and genera) and vertebrates (usually rodents and small mammals, which support the transmission of the TBEV). Details of these transmission cycles and the animal species involved are described in Chapter 3. However, at the moment it is not clear which ecological structures and requirements are needed to establish and maintain a TBE natural focus. A sufficient number of ticks that are infected or might be susceptible to infection must be present. Also, a sufficient number of susceptible small mammals to support virus transmission is required. There must also be an adequate number of larger animals to support the developmental cycle of the nymphs and adult stages of the tick vectors, as these are rarely found on rodents. The virus itself is transmitted via viremic vertebrates or via co-feeding of TBEV-infected ticks together with non-infected ticks, with the latter transmission mechanism being more effective. However, so far, no proof exists as to the actual importance of any of these mechanisms in the field.

A number of models on natural foci of TBEV are now available, but fieldwork is missing. In the early 1960s Austrian researchers were studying TBE foci in Austria.<sup>6</sup> According to the authors' data and estimates, focus size was 60,000 m<sup>2</sup> with an estimated 2 million larvae and about 500,000 nymphs in the focus. They estimated that between 500 and 1500 nymphs (0.1% to 0.3%) are infected at any time in the year and may infect 15 to 30 rodents out of an estimated total number of 700 rodents in the focus. They found a total of 4 small mammal species with a clear dominance of *Apodemus* spp. (*Apodemus flavicollis* > *Apodemus sylvaticus* > *Myodes glareolus* > *Microtus agrestis*). The focus was highly fragmented into old forests, young forests, and meadows that existed within the forests.

Nosek et al.<sup>7</sup> described the structure of TBE natural foci in the Czech Republic. Their work showed that a focus is maintained by a number of so-called microfoci. The size of the natural focus is not given. The authors estimate that per 10,000 m<sup>2</sup> (1 ha) the number of ticks ranges from 15,000 to 50,000 nymphs. A microfoculus is defined as a structure in the focus area where virus transmission is continuously active and therefore the virus can be generally detected. The rate of positive ticks in the microfoculus is approximately 0.5% to 1% in nymphs and up to 5% in adult ticks.


In a recent study over 4 years in a TBE focus in Hungary, the authors reported that an area of 36 ha (3,600,000 m<sup>2</sup>) was screened and that only in an area of 0.49 ha (4900 m<sup>2</sup>) seropositive rodents were detected.<sup>8</sup> They found TBEV in a total of 3 tick pools (2 pools of *Ixodes ricinus* and 1 pool of *Haemaphysalis concinna*) out of 7247 sampled ticks (0.05%). Of note, in an area around 170 m away from the focus but in the same natural focus area, no TBEV was detected among 2369 sampled ticks. This description supports our own observation on TBE natural foci in southeastern Germany<sup>9</sup> that a TBE natural focus has a size of about 5000 to 10,000 m<sup>2</sup>. The main ecological structure, which can be identified as important in the focus, is the ecotone between forest and meadow. More data must be collected in the field to get a clear picture of the ecological structure that is required for the development and maintenance of a TBE natural focus.

## The phylogeny and phylo-geography of TBEV

According to phylogenetic studies at least 3 and possibly 6 subtypes of the TBEV can be genetically distinguished by molecular technologies. At present, 3 subtypes of TBEV—the European (western) subtype (TBEV-EU), the Siberian subtype (TBEV-SIB), and the Far-Eastern subtype (TBEV-FE)—are recognized. Russian virologists have claimed 2 new subtypes, strain 178-19 and strain 886-84, both isolated in the Lake Baikal region in Siberia.<sup>10</sup> Also, a new putative



**Figure 2: Eurasian TBE focus regions classified after Korenberg et al.**<sup>5</sup>  
 (1) Central European-Mediterranean; (2) Eastern European; (3) Western Siberian; (4) Central Siberian-Trans-Baikalian;  
 (5) Khyngan-Amur; (6) Pacific; (7) Krim-Caucasian; (8) Kazakh-Central Asian



TBEV Himalayan subtype was claimed in China.<sup>84</sup> The European subtype differs by 4% to 6% from the other 2 subtypes (amino acid sequence). The Siberian and Far-Eastern subtypes also differ by 4% to 6% in amino acid sequence from each other.

Phylogenetic analysis shows that the TBEV group separated from the other flaviviruses about 30,000 years ago in Central Africa. From there, the tick-borne flavivirus ancestors migrated east and arrived in central Siberia about 7,500 years ago. The virus ancestor then divided into a western branch and an eastern branch. The eastern branch developed into the Siberian and Far-Eastern subtypes plus also into potentially 2 newly identified subtypes. This evolutionary development took about 3,000 years. The western branch spread to Central Europe and further evolved on the British Isles into Louping ill virus and on the Iberian Peninsula into the Spanish sheep encephalitis virus.<sup>11</sup>

In Western Europe, TBEV-EU is prevalent. However, in the Baltic countries and in parts of Finland, the Siberian and Far-Eastern subtype virus strains have been isolated and identified. So far, it is not clear whether the Siberian subtype in particular moves in a western direction. However, identification of virus strains in Siberia shows that a few of the strains circulating in Siberia belong to the European and Far-Eastern subtypes. According to results from Russian investigators, the Siberian subtype invaded the Baltic countries only recently, coincidentally with the construction of the Trans-Siberian Highway and the Trans-Siberian Railway.<sup>12</sup> Also, the European subtype has been detected in South Korea and also in Siberia.<sup>13,14</sup> Improved understanding of the phylogeography of these strains will require additional studies.

### European subtype

The European subtype (formerly known as the “Western subtype”) of TBEV is prevalent in Europe. However, the distribution ranges from France and The Netherlands at its western limit of distribution to South Korea, the easternmost region where TBEV-EU has been detected so far.<sup>9,13,15</sup> While only TBEV-EU is found in Central Europe, more than 80% of identified strains in the Baltics belong to the European subtype. In Western and Eastern Siberia, only a low percentage (<10%) of the identified TBEV strains is characterized as European subtype. As noted, some other TBEV-EU strains have been identified and isolated in South Korea.<sup>13,16,17</sup>

According to phylogenetic data, TBEV-EU is the youngest of all TBEV subtypes.<sup>11</sup> These data indicate that about 3,000 years ago the European strain diverged from the ancestor virus and migrated westwards. Some evidence suggests that the TBEV strains in Central Europe originated in the Czech Republic. From there the virus migrated about 350 years

ago to Germany.<sup>18</sup> Several waves of spreading and migration seem to have occurred. In Germany intensive studies on particular TBE foci show that in each TBE focus, a particular and clearly identifiable virus strain is prevalent. The TBEV strains seem to be stable in their E gene sequences for decades as shown in Finland (Kumlinge strain) and in Austria (Zillertal strain).<sup>9</sup> However, no clear pattern of viral spread exists that can be correlated to landscapes or to human activities to explain the introduction of the Siberian and Far-Eastern subtypes in the Baltic region. Analysis of the E genes of TBEVs from different strains shows a kind of geographic clustering e.g. in Scandinavia, Germany, the Czech Republic or the Slovak Republic (Slovakia). But there are also some strains that are genetically related to strains from greater distances, e.g. German strains that are similar to Russian or Scandinavian strains. It is unclear at the moment whether these genetic relationships are due to missing link strains. A clear classification of European strains into genetic clusters or branches is still missing and awaits the analysis of more strains from different parts of Europe.

The phylogenetic analysis of TBEV-EU is unclear and confusing. For about 3,000 years, when the European strain branched off from the ancestor virus and migrated westward, TBEV-EU appears to have remained monophyletic. All currently known strains from Central Europe separated only about 300 to 400 years ago.<sup>11</sup> In contrast to the Siberian subtype, the European subtype shows a parallel evolution. All currently known strains seem to originate from a single genetic clade. In contrast, the Siberian subtype shows a more consecutive genetic evolution. Only recently, a TBEV strain from The Netherlands was shown to have a distant genomic relationship to all other TBEV-EU strains. While TBEV-EU has also been identified and isolated outside Europe, the phylogenetic connection between European strains and the Siberian and Korean strains is as yet unclear.

A number of phenotypic characterizations have demonstrated TBEV strains of differing pathogenicity, which are circulating in nature. The TBEV strain MucAr HB171/11 shows low neuropathogenicity and neuro-invasiveness in a mouse model.<sup>9</sup> A Czech strain, ts263, is a temperature-sensitive strain that does not grow at 40°C and also exhibits non-neuro-invasiveness.<sup>19</sup>

In addition, TBEV-EU is mainly associated with the biphasic form of TBE. So far, no chronic forms of disease caused by TBEV-EU have been reported. The clinical picture of infection ranges from subclinical to febrile disease to CNS symptoms with severe and persisting neurological sequelae in up to 10% of human cases. The fatality rate of infections with TBEV-EU ranges from 1% to 2%. Acute fatal cases have been rare since a fast-acting treatment of brain edema was introduced. Disease sequelae and fatal cases are mainly



seen in elderly patients. The fatalities often result from super-infections (e.g. pneumonia) relating to the neurological sequelae (e.g. paralysis of breathing muscles); therefore these conditions must be named as indirect causes of fatalities due to TBE.


### Far-Eastern subtype

The TBEV-FE viral subtype can be primarily found in the territory of the far-eastern part of Eurasia.<sup>20–27</sup> However, this subtype was detected in other regions of Eurasia, including the Baltic countries, the Crimean Peninsula, the Republic of Moldova, the Republic of Belarus, and the territories of Komi Republic, Republic of Bashkortostan, Ural Mountains, Siberia, and the European part of Russia.<sup>10,28–32</sup> In some territories, TBEV-FE has been more prevalent in urban and suburban areas.<sup>33,34</sup> Also, TBEV-FE can cause different forms of disease, from subclinical to acute.<sup>35,36</sup>

Within this subtype at least 4 separate groups (lineages) of TBEV have been described (Fig. 3). The first group consists of TBEV strains similar to the Sofjin strain, which was isolated in the Khabarovsk region of Russia in 1937 from a patient's brain (Zil'ber, 1939)<sup>1</sup> and includes strains from far eastern Russia, Japan, China, Latvia, and the European part of Russia.<sup>26,27</sup> The group of strains similar to the Oshima strains isolated in Japan on Hokkaido Island forms a separate cluster on phylogenetic dendrograms that is significantly different from the Sofjin strains group<sup>20–22</sup> and includes TBEV strains from Japan, China, and the Crimean peninsula.<sup>26,27</sup> The third group consists of the Chinese Senzhang strain, which was isolated from a patient's brain in 1953;<sup>24</sup> the MGJ-01 strain, which was obtained from a patient's blood serum and used in China for the production of vaccines and immunobiologic drugs;<sup>37</sup> and other strains from far eastern Russia. In addition, the fourth group formed by TBEV-FE strains from Japan (Kam586/97(AB237185), Kam588/97(AB237186)) has been described.<sup>27</sup> The time of divergence among different TBEV-FE clusters within the Far-Eastern subtype was estimated at approximately 470 to 650 years ago (Fig. 3).

Also, within TBEV-EU some unique virus variants have been described. In 1999, in the southeast of the Novosibirsk region of Western Siberia, Russia, cases of hemorrhagic forms of TBE with fatal outcomes were reported.<sup>38</sup> Previously, infections resulting in a hemorrhagic disease had not been described for TBEV, although other tick-borne flaviviruses such as Omsk hemorrhagic fever virus and Kyasanur forest disease virus may cause blood-clotting (see section 6 below). The sequencing of the E gene fragment of 6 samples (Figure 3) shows that these TBEV variants corresponded to TBEV-FE, and a number of observed nucleotide substitutions (and amino acid substitutions in the corresponding E protein fragment) were not previously described. Thus, the appearance of new variants of highly

**Figure 3:** The fragment of the TBEV dendrogram corresponding to TBEV-FE strains<sup>27</sup>



pathogenic, atypical TBEV can be evidence of the continuing evolution of this virus group.

In 2004, the TBEV Glubinnoe/2004 strain was isolated from the brain of a deceased patient in the Primorsky region of far eastern Russia. The sequencing of its genome demonstrated that this TBEV variant corresponds to TBEV-FE, but has 53 or 57 substitutions in polyprotein amino acid sequence compared with Far-Eastern strains 205 (DQ989336)<sup>39</sup> or Sofjin-HO (AB062064),<sup>40</sup> respectively, and 14 of these substitutions are unique and have not been described previously.<sup>41</sup> Researchers also found that Glubinnoe/2004 has a high level of production of infectious viral particles during the early stages of infection in cell cultures as compared with other Far-Eastern 205 strains.<sup>41</sup>

### Siberian subtype

The TBEV-SIB subtype is the most common TBEV and has been found almost everywhere in TBEV habitat areas. Thus, it has been detected in most parts of Russia, including the central and northwestern regions, Ural Mountains, Western and Eastern Siberia, the Far East, etc.,<sup>10,12,28,42–44</sup> as well as in Mongolia,<sup>45</sup> Kazakhstan and Kyrgyzstan,<sup>46–49</sup> Finland and the Baltic countries,<sup>12,50</sup> Ukraine,<sup>28,49</sup> and the Balkan peninsula.<sup>49</sup>



TBEV-SIB is believed to be the most genetically heterogeneous, with a nucleotide substitution level about 5.4% within the subtype.<sup>51</sup> At first, based on the analysis of E protein sequences at amino acid positions 234 and 431, two genetic lineages were defined: one lineage including Zausaev strain (AF527415) was characterized by H234/A431, whereas strains of the second lineage including Vasilchenko strain (AF069066) revealed Q234/T431.<sup>52,53</sup> Later, the "Baltic lineage"<sup>50,54-56</sup> and "European topovariant"<sup>57</sup> of TBEV-Sib were described. Also, the heterogeneity of TBEV-Sib was demonstrated by molecular hybridization of nucleic acids with 2 subgenotype-specific probes (designated as 3a and 3b) differentiating lineages/subgenotypes "Vasilchenko" and "Zausaev" of Siberian subtype (Fig. 4).<sup>10</sup> The Zausaev and Vasilchenko lineages were found in various regions of Eurasia at different ratios, and moreover, some TBEV strains of Siberian subtype could not be attributed to any of these lineages.


### Baikalian subtype

In addition to the 3 primary and accepted TBEV subtypes, 2 groups of TBEV strains supposed to be new TBEV subtypes were described. At this time, the members of now accepted fourth prototype strain 886-84 (EF469662, KJ633033) subtype have been found only in the Republic of Buryatia, in

the Irkutsk and Chita regions of Eastern Siberia and in northern Mongolia (Fig. 5).<sup>10,21,51</sup> This subtype is also now named "Baikalian subtype" and about 20 TBEV strains have been identified and genetically characterized.<sup>10,49,51</sup> These strains (called the "886-84 group") form an independent cluster on the TBEV dendrogram (see Chapter 2) and have no close homology with any strains of the 3 original subtypes. Within the group, high homology (more than 98%) of nucleotide sequences was observed while the genetic differences with other subtypes were shown to be greater than 12%.<sup>51</sup>

TBEV strains of the Baikalian subtype were isolated from ticks and small mammals collected in the Irkutsk region, Buryat Republic, and Transbaikalia in 1984-1990 indicating their ecological connection with all elements of transmission chain. Despite the fact that these strains were isolated over 20 years ago, their circulation probably continues in natural foci. Thus, 2 TBEV strains similar to the reference strain of the Baikalian subtype were described recently in the territory of Transbaikalia from a taiga tick (in 1999) and 1 strain from *Myodes rutilus* (in 2010).<sup>58,59</sup> Also, in 2010, a report was published on a case of fatal meningoencephalitis in Mongolia caused by a TBEV isolate having a high degree of homology in the E gene fragment (98.5%) with strains of the 886-84 group.<sup>60</sup> The case was

**Figure 4:** Correlation and distribution of TBEV genotype 3 subgenotypes throughout the whole sampling area and Eastern Siberia. Altogether, 197 strains were typed using oligonucleotide probes<sup>10</sup>



**Figure 5:** Habitat area of TBEV group “886-84” strains

described in Bulganskiy province, bordering to the south with foci where TBEV group 886-84 strains had been isolated previously. The patient was hospitalized with meningoencephalitis on the 11th day after a tick bite and then died that same day. The presence of TBEV RNA in macromyelom samples, in the core and the *meninx vasculosa*, demonstrated the multilevel localization of lesions and was typical of the most severe forms of acute TBE that result in death or disability.<sup>60</sup>

The analysis of complete amino acid sequences of polyprotein from some strains confirmed that it is a “mixture” of sequences common for the 3 genotypes. Twenty-nine unique substitutions were detected that could probably be genotype-specific for group 886 members.<sup>51</sup> The studies of biological properties demonstrated that group 886 strains have a wide spectrum of antigenic properties, hemagglutination and neutralizing activities, high virulence, and thermotolerance.

### Other putative subtypes

Besides the now four accepted subtypes there are two genetically distant groups of viruses, which show high genetic distance to all known TBE virus strains. One virus was isolated only once. The prototype strain which is named “strain 178-79” (EF469661) and was isolated in 1979 from a tick pool of *Ixodes persulcatus*.<sup>10</sup> The single available isolate and genome sequence show 10 to 16% difference to

other TBEV subtypes on nucleotide level and 3 to 6% difference on amino acid level.<sup>10</sup>

Chinese researchers reported on another new TBEV subtype.<sup>84</sup> Two TBEV sequences were detected in two specimens of *Marmota himalayana*, collected in the Haixi prefecture at an altitude of 2,994m in the Qinghai-Tibet Plateau in China. So far, no virus isolates are reported. Only the sequence of the complete genome and of the viral polyprotein have been available. According to these data, the virus differs in 16 to 18% on nucleotide level and in 6 to 8% on amino acid level from all other TBEV subtypes. According to a phylogenetic analysis the putative new subtype diverged earlier from the Far-eastern subtype than the Siberian subtype.

### Seroepidemiology in humans

From the start of the use of antibody testing in this field, the prevalence rates of antibodies against TBEV (and other pathogens) were used to estimate the burden of infection as well as the burden of disease in human populations. Although these rates depend on a number of different factors (such as a person’s age, profession, leisure activities, place of living, interest in nature/outdoor activities, degree of protection measures, knowledge about disease and transmission, and vaccination status, as well as presence of cross-reacting viruses, assay technology used, etc.), the data



at least serve as a rough indication for the presence or absence of TBE in an area.

In determining TBE seroprevalence rates, studies in the normal population have to be distinguished from studies and their results in highly exposed professionals such as woodcutters, farmers, or hunters. In European countries, the available seroprevalence rates in different countries in the normal population range from 0% to 39%. However, the highest of these values are usually found in special

**Table 1:** Seroprevalence of anti-TBE antibodies in normal populations of different European countries

Country	Prevalence (%)	Literature
Bornholm (Denmark)	1.4	Kristiansen <sup>17</sup>
Estonia	0-5	Vasilenko et al. <sup>72</sup>
Archipel (Finland)	5	Han et al. <sup>73</sup>
Lithuania	3	Juceviciene et al. <sup>74</sup>
Norway	2.4	Skapaas et al. <sup>75</sup>
Poland (North)	4.8-6.5	Anonymous 1983
Czech Republic	15-28	Gresikova 1988 <sup>76</sup>
Switzerland	0.5-5.0	Matile et al. 1979 <sup>77</sup>
Hunchun (China)	10.9	Satz 2006 <sup>78</sup>

geographic conditions, for example 39% on Finnish islands in the Baltic Sea. Usually the seroprevalence rates in European populations range from 0% to 5% (Table 1).

While other studies on the prevalence rates in high-risk populations resulted in similar rates, some also indicated more extreme values under special conditions, e.g. >30% to 40% in some groups of forest workers in Poland (Table 2).

These data showed that the risk of acquiring TBE infection might be high, both in an exposed general population and in a high-risk population. However, many of these studies were conducted before the introduction of vaccines. Therefore, awareness of the disease among the general population in rural areas was low and personal protection measures usually were not applied. This might be one reason why in some areas the seroprevalence rates in the normal population might be in a similar range as seen in highly exposed groups.

## Seroepidemiology in animals

Humans are not natural hosts of the TBEV. Therefore, the seroprevalence rates in humans usually give an incomplete picture of TBEV epidemiology. During the past few decades, a number of studies have been undertaken to study the seroprevalence rates in different species of wild and domestic animals. The seroprevalence rates of particular animals can document the presence of a transmission cycle.

**Table 2:** Seroprevalence of anti-TBE antibodies in high-risk populations of different European countries

Country	Risk group	Prevalence (%)	Literature
Bornholm (Denmark)	Forest worker	16	Kristiansen <sup>71</sup>
Germany	Forest worker	5.6-7.2	Satz <sup>78</sup>
Alsace (France)	Forest worker	8	Collard et al. <sup>79</sup>
Poland (North)	Forest worker	20-40	Satz <sup>78</sup>
Switzerland	Forest worker	4.7	Matile et al. <sup>77</sup>
Hungary	Forest worker	3.3	Molnar <sup>80</sup>

These data may also help with understanding the intensity of transmission in the natural cycle. In addition, they may document the role of particular animals in virus transmission and in the maintenance of the TBE transmission cycle. Recently, data on the prevalence of antibodies and virus were tested in wild and domestic animals to identify species that might be used as surrogates for detection of endemic areas.

The role of particular mice and voles, *Apodemus flavicollis* and *Myodes glareolus*, respectively, as primary vertebrate hosts for the virus in the transmission cycle was demonstrated in a number of isolations of virus strains in TBE natural foci and through experimental infections.<sup>61-63</sup> Also, *Apodemus sylvaticus* seems to support the transmission cycle as evidenced by high seroprevalence rates in Switzerland.<sup>64</sup> In a recent study, Achazi et al.<sup>65</sup> detected TBEV using molecular techniques in 6 rodent species in Germany: *Apodemus agrarius*, *Apodemus flavicollis*, *Apodemus sylvaticus*, *Microtus arvalis*, *Microtus agrestis*, and *Myodes glareolus*. The seroprevalence rates in rodents of different areas ranged from 0% to 72% (Table 3).

While the role of mice (Muridae) and voles (Cricetidae) for TBEV transmission seems clear, the importance of Insectivora is still not finally clarified. Different studies show that hedgehogs (Erinaceidae) are highly infested with ticks. Kozuch et al.<sup>62</sup> detected up to 50% seroprevalence rates in hedgehogs in a study in Slovakia, and they could isolate a strain of TBEV from the hedgehog. Even less clear is the role of shrews (Soricidae). However, TBEV was isolated from a brain of a common shrew, *Sorex araneus*.<sup>66</sup> According to early studies, the common mole (*Talpa europaea*) produces high viremia and therefore may act as a maintenance host in the natural transmission cycle. Systematic seroprevalence data on TBE antibodies in insectivores are not available.

In addition, seroprevalence studies in foxes and correlations with human TBE are limited. One study on TBEV seroprevalence in foxes from different areas in Germany found prevalence rates from 0% in Brandenburg to 10% in the Odenwald and Taunus region (a known endemic area of low activity) to 35% in the Black Forest area, a highly

**Table 3:** Seroprevalence of anti-TBE antibodies in wild animals in different European countries

Country	Vertebrate	Prevalence (%)	Literature
Bornholm Archipel( Denmark)	Deer	83	Freundt <sup>69</sup>
Aland Archipel (Finland)	Rodents	0.5	Han et al. <sup>81</sup>
Austria	Yellow-necked mouse	47.9	Labuda et al. <sup>82</sup>
Austria	Bank voles	29.4	Labuda et al. <sup>70</sup>
Slovakia	Deer	35.3	Labuda et al. <sup>70</sup>
Slovakia	Boar	36.8	Labuda et al. <sup>70</sup>
Slovakia	Rodents	14	Labuda et al. <sup>70</sup>
Czech Republic	Rodents	14.6	Gresikova et. al. <sup>83</sup>

endemic region for TBE.<sup>67</sup> Also a number of game animals have been tested as indicator animals for TBEV circulation.

These studies, in Germany but also in other European countries (e.g. Denmark), showed high seroprevalence rates against TBEV. Studies in Germany showed the seroprevalence rate in red deer and reindeer in the former German Democratic Republic was up to 72% positive.<sup>68</sup> A similar rate of 83% was reported in a study from the Danish island of Bornholm, also in the red deer population.<sup>69</sup> A study in red deer from Slovakia showed lower antibody rates of 35%.<sup>70</sup>

In natural transmission cycles of the boskematic type, the testing of antibody rates in farm animals may give good evidence of TBEV transmission and also of the risk of alimentary TBEV transmission. Therefore, a number of seroprevalence studies in cows, sheep, and goats from different countries are also available. In most available studies, these data show that the seroprevalence rate is around 5%. There are some exceptions in Germany. In the former German Democratic Republic, an antibody prevalence rate of 60% in cows was reported.<sup>68</sup> A recent study in several federal states of Germany revealed seroprevalence rates of 0% to 43% in goats and sheep.<sup>85</sup> The patchy distribution of high antibody rates in these animals correlated only in part with the presence of human TBE disease.

### Other tick-borne mammalian flaviviruses

The International Committee on the Taxonomy of Viruses (ICTV) lists in the genus *Flavivirus* a total of eight tick-borne mammalian flavivirus (TBMF) species. They distinguish single virus species according to several characteristics:

- Nucleotide and deduced amino acid sequence data.
- Antigenic characteristics.
- Geographic association.
- Vector association.
- Host association.
- Disease association.
- Ecological characteristics.

However, this actual species description no longer includes many of the known and ecologically different TBMF, as no virus subtypes or strains below species level are listed. However, there is a number of flaviviruses with specific names often found in literature, which cause severe human and animal disease. The known subtypes of TBMF are listed in Table 4 including some features regarding their geographical distribution and epidemiology. All viruses listed are genetically closely related to the viruses of the TBEV complex. Therefore besides their medical and veterinary importance they also play a role regarding the diagnosis of flavivirus diseases due to cross-reactivity of antibodies with TBEV antibodies in areas of overlapping geographical distribution. For some of the viruses (Omsk hemorrhagic fever, Louping ill virus Kyasanur Forest disease virus) in laboratory tests the neutralizing cross-reaction of TBEV vaccine-induced antibodies was shown. However, no data are available on the field effectiveness of TBEV vaccines against these viruses.

**Table 4: Viruses and virus subtypes of the tick-borne mammalian flavivirus complex of the tick-borne flavivirus group**

Virus	Virus type/-subtype	Clinical symptoms in humans/in animals	Geographical distribution	Vector
Louping ill virus	Louping ill virus	Meningoencephalitis Louping ill in sheep	British Islands; possibly Norway	<i>Ixodes ricinus</i>
	Turkish sheep encephalitis virus	No human disease known; encephalitis in sheep	Turkey	Unknown
	Greek goat encephalitis virus	No human disease known; encephalitis in goats	Northern Greece	<i>Ixodes ricinus</i>
	Spanish sheep encephalitis virus	No human disease known; encephalitis in sheep	Spain	Unknown
	Spanish goat encephalitis virus	No human disease known	Northern Spain	Unknown
	Negishi virus	Meningoencephalitis	Japan	<i>Ixodes ricinus</i> ; <i>Ixodes persulcatus</i>
Omsk hemorrhagic fever virus	Omsk hemorrhagic fever virus	Hemorrhagic fever	Western Siberia	<i>Ixodes apronophorus</i> , <i>Dermacentor</i> spp.
Kyzasur Forest virus	Kyzasur Forest virus	Hemorrhagic fever	Southwestern India; possibly China	<i>Haemaphysalis</i> spp.
	Alkhumra virus	Hemorrhagic fever	Arabian Peninsula; Egypt	<i>Ornithodoros</i> spp.
Powassan virus	Powassan virus	Meningoencephalitis	Northern America; Far east of Russia	<i>Ixodes</i> spp.; <i>Dermacentor</i> spp. (?)
	Deer tick virus	Meningoencephalitis	East coast of Northern America	<i>Ixodes scapularis</i> ; <i>Dermacentor andersoni</i>
Langat virus	Langat virus	Meningoencephalitis in severely immunocompromised patients	Malaysia to Central Siberia	<i>Haemaphysalis</i> spp.

**Acknowledgments:**

ST was supported by State funded budget project of ICBFM SB RAS #AAAA-A17-117020210027-9.

**Contact:** gerharddobler@bundeswehr.org

**Citation:** Dober G, Tkachev S. General epidemiology of TBE. Chapter 11. In: Dobler G, Erber W, Bröker M, Schmitt HJ, eds: *The TBE Book*. 5th ed. Singapore: Global Health Press; 2022. doi : 10.33442/26613980\_11-5

**References**

- Zil'ber LA. Spring (spring-summer) epidemic tick-borne encephalitis. *Arch Biol Nauk*. 1939;56:9-37.
- Pavlovsky EN. *Natural Nidality of Transmissible Diseases*. (Translated and edited by N.D. Levine). Urbana, IL: University of Illinois Press; 1966.
- Rosicky B. Notes on the classification of natural foci of tick-borne encephalitis in Central and South-East Europe. *J Hyg Epidemiol Microbiol Immunol*. 1959;3:431-43.
- Blaskovic D, Nosek J. The ecological approach to the study of tick-borne encephalitis. *Prog Med Virol*. 1972;14:275-320.

5. Korenberg E, Kovalevskii YV. Main features of tick-borne encephalitis eco-epidemiology in Russia. *Zentralbl Bakteriol.* 1999;289:525-39.
6. Pretzmann G, Loew J, Radda A. Research on a natural focus of early summer meningoencephalitis (FSME) in lower Austria. 3. Attempt at a demonstration in toto of the cycle of FSME in the natural endemic focus. *Zentralbl Bakteriol Orig.* 1963;190:299-312.
7. Nosek J, Kozuch O, Radda A. Studies of the ecology of the Central European tick-borne encephalitis virus in Northern Moravia. *Zentralbl Bakteriol Orig.* 1968;208:81-7.
8. Zoldi V, Papp T, Rigo K, Farkas J, Egyed L. A 4-year study of a natural tick-borne encephalitis virus focus in Hungary, 2010-2013. *Ecohealth.* 2015;12:174-82.
9. Dobler G, Gniel D, Petermann R, Pfeffer M. Epidemiology and distribution of tick-borne encephalitis. *Wien Med Wochenschr.* 2012;162:230-8.
10. Demina TV, Dzhioev YP, Verkhozina MM, et al. Genotyping and characterization of the geographical distribution of tick-borne encephalitis virus variants with a set of molecular probes. *J Med Virol.* 2010;82:965-76.
11. Heinze DM, Gould EA, Forrester NL. Revisiting the clinal concept of evolution and dispersal for the tick-borne flaviviruses by using phylogenetic and biogeographic analyses. *J Virol.* 2012;86:8663-71.
12. Kovalev SY, Chernykh DN, Kokorev VS, Snitkovskaya TE, Romanenko VV. Origin and distribution of tick-borne encephalitis virus strains of the Siberian subtype in the Middle Urals, the north-west of Russia and the Baltic countries. *J Gen Virol.* 2009;90:2884-92.
13. Kim SY, Yun SM, Han MG, et al. Isolation of tick-borne encephalitis viruses from wild rodents, South Korea. *Vector Borne Zoonotic Dis.* 2008;8:7-13.
14. Demina TV, Tkachev SE, Kozlova IV, et al. Comparative analysis of complete genome sequences of European subtype tick-borne encephalitis virus strains isolated from *Ixodes persulcatus* ticks, long-tailed ground squirrel (*Spermophilus undulatus*), and human blood in the Asian part of Russia. *Ticks Tick Borne Dis.* 2017;8:547-53.
15. Herpe B, Schuffenecker I, Pillot J, et al. Tick-borne encephalitis, southwestern France. *Emerg Infect Dis.* 2007;13:1114-6.
16. Kim SY, Jeong YE, Yun SM, Lee IY, Han MG, Ju YR. Molecular evidence for tick-borne encephalitis virus in ticks in South Korea. *Med Vet Entomol.* 2009;23:15-20.
17. Yun SM, Kim SY, Ju YR, Han MG, Jeong YE, Ryou J. First complete genomic characterization of two tick-borne encephalitis virus isolates obtained from wild rodents in South Korea. *Virus Genes.* 2011;42:307-16.
18. Weidmann M, Ruzek D, Krivanec K, et al. Relation of genetic phylogeny and geographical distance of tick-borne encephalitis virus in central Europe. *J Gen Virol.* 2011;92:1906-16.
19. Kopecky J, Krivanec K, Tomkova E. Attenuated temperature-sensitive mutants of tick-borne encephalitis (TBE) virus isolated from natural focus. In: *Modern Acarology, Vol. 2.* Eds Dusbábek F, Bukva V. The Hague: Academia, Prague and SPB Academic Publishing bv; 1991:11-9.
20. Hayasaka D, Suzuki Y, Kariwa H, et al. Phylogenetic and virulence analysis of tick-borne encephalitis viruses from Japan and far-Eastern Russia. *J Gen Virol.* 1999;80 (Pt 12):3127-35.
21. Zlobin VI, Demina TV, Mamaev LV, et al. Analysis of genetic variability of strains of tick-borne encephalitis virus by primary structure of a fragment of the membrane protein E gene. *Vopr Virusol.* 2001;46:12-6.
22. Zlobin VI, Demina TV, Belikov SI, et al. Genetic typing of tick-borne encephalitis virus based on an analysis of the levels of homology of a membrane protein gene fragment. *Vopr Virusol.* 2001;46:17-22.
23. Pogodina VV, Bochkova NG, Karan LS, et al. The Siberian and Far-Eastern subtypes of tick-borne encephalitis virus registered in Russia's Asian regions: genetic and antigen characteristics of the strains. *Vopr Virusol.* 2004;49:20-5.
24. Song H, Wang H, Wang P, et al. Design and application of M-RT-PCR diagnostic methods for arboviral encephalitis. *J Microbiol Immunol.* 2004;24:317-23.
25. Leonova GN, Belikov SI, Pavlenko EV, Kulakova NV, Krylova NV. Biological and molecular genetic characteristics of a Far-Eastern tick-borne encephalitis virus population and its pathogenetic implication. *Vopr Virusol.* 2007;52:13-7.
26. Si B-Y, Jiang T, Zhang Y, et al. Complete genome sequence analysis of tick-borne encephalitis viruses isolated in northeastern China. *Arch Virol.* 2011;156:1485-8.
27. Subbotina EL, Loktev VB. Molecular evolution of the tick-borne encephalitis and Powassan viruses. *Mol Biol (Mosk).* 2012;46:82-92.
28. Adel'shin RV, Zlobin VI, Belikov S, et al. Molecular epidemiology of tick-borne encephalitis in European part of Russia and some countries of Baltics, Eastern and South-Eastern Europe. *Epidemiology and Vaccinal Prevention.* 2006;2:27-3.
29. Chaousov EV, Ternovoi VA, Protopopova EV, et al. Variability of the tick-borne encephalitis virus genome in the 5' noncoding region derived from ticks *Ixodes persulcatus* and *Ixodes pavlovskyi* in Western Siberia. *Vector Borne Zoonotic Dis.* 2010;10:365-75.
30. Glushakova L, Korabel'nikov IV, Ternovoi VA, et al. Detection of causative agents in *Ixodes persulcatus* in the Komi

- Republic. *Siberian Med J.* 2012;111:88-91.
31. Hubalek Z, Rudolf I. Tick-borne viruses in Europe. *Parasitol Res.* 2012;111:9-36.
  32. Ponomareva EP, Mikryukova TP, Gori AV, et al. Detection of Far-Eastern subtype of tick-borne encephalitis viral RNA in ticks collected in the Republic of Moldova. *J Vector Borne Dis.* 2015;52:334-6.
  33. Iurchenko OA, Vinograd NA, Dubina DA. Molecular genetic characteristics of tick-borne encephalitis virus in the Crimea. *Vopr Virusol.* 2012;57:40-3.
  34. Mikryukova TP, Moskvitina NS, Kononova YV, et al. Surveillance of tick-borne encephalitis virus in wild birds and ticks in Tomsk city and its suburbs (Western Siberia). *Ticks Tick Borne Dis.* 2014;5:145-51.
  35. Tkachev SE, Fomenko NV, Rar VA, Igolkina YP, Kazakova YV, Chernousova NY. PCR-detection and molecular-genetic analysis of tick-transmitted pathogens in patients of Novosibirsk region, Russia. *Int J Med Microbiol.* 2008;298(S1):365-7.
  36. Leonova GN, Belikov SI, Kondratov IG, Takashima I. Comprehensive assessment of the genetics and virulence of tick-borne encephalitis virus strains isolated from patients with inapparent and clinical forms of the infection in the Russian Far East. *Virology.* 2013;443:89-98.
  37. Lu Z, Broker M, Liang G. Tick-borne encephalitis in mainland China. *Vector Borne Zoonotic Dis.* 2008;8:713-20.
  38. Ternovoi VA, Kurzhuikov GP, Sokolov YV, et al. Tick-borne encephalitis with hemorrhagic syndrome, Novosibirsk region, Russia, 1999. *Emerg Infect Dis.* 2003;9:743-6.
  39. Safronov PF, Netesov SV, Mikriukova TP, et al. Nucleotide sequence of genes and complete amino acid sequence of tick-borne encephalitis virus strain 205. *Mol Gen Mikrobiol Virusol.* 1991:23-9.
  40. Goto A, Hayasaka D, Yoshii K, Mizutani T, Kariwa H, Takashima I. Genetic and biological comparison of tick-borne encephalitis viruses from Hokkaido and far-eastern Russia. *Jpn J Vet Res.* 2002;49:297-307.
  41. Ternovoi VA, Protopopova EV, Chausov EV, et al. Novel variant of tickborne encephalitis virus, Russia. *Emerg Infect Dis.* 2007;13:1574-8.
  42. Bakhvalova VN, Rar VA, Tkachev SE, et al. Tick-borne encephalitis virus strains of Western Siberia. *Virus Res.* 2000;70:1-12.
  43. Pogodina VV. Monitoring of tick-borne encephalitis virus populations and etiological structure of morbidity over 60 years. *Vopr Virusol.* 2005;50:7-13.
  44. Tkachev SE, Demina TV, Dzhioev YP, et al. Genetic studies of tick-borne encephalitis virus strains from Western and Eastern Siberia. In: *Flavivirus Encephalitis.* Ed Růžek D: InTech; 2011:235-54.
  45. Frey S, Mossbrugger I, Altantuul D, et al. Isolation, preliminary characterization, and full-genome analyses of tick-borne encephalitis virus from Mongolia. *Virus Genes.* 2012;45:413-25.
  46. L'Vov D K, Al'khovskii SV, Shchelkanov M, et al. Genetic characterisation of Powassan virus (POWV) isolated from Haemophysalis longicornis ticks in Primorye and two strains of Tick-borne encephalitis virus (TBEV) (Flaviviridae, Flavivirus): Alma-Arasan virus (AAV) isolated from Ixodes persulcatus ticks in Kazakhstan and Malyshevo virus isolated from Aedes vexans nipponii mosquitoes in Khabarovsk kray. *Vopr Virusol.* 2014;59:18-22.
  47. Abdiyeva K, Turebekov N, Shapiyeva Z, et al. The South of Kazakhstan is a hotspot for the Siberian Subtype of tick-borne encephalitis virus. 15th Medical Biodefense Conference Abstracts; 2016; Munich, 26-29 April, 2016:31.
  48. Hay J, Yeh KB, Dasgupta D, et al. Biosurveillance in Central Asia: Successes and Challenges of Tick-Borne Disease Research in Kazakhstan and Kyrgyzstan. *Front Public Health.* 2016;4:4.
  49. Tkachev SE, Tikunov AY, Babkin IV, et al. Occurrence and genetic variability of Kemerovo virus in Ixodes ticks from different regions of Western Siberia, Russia and Kazakhstan. *Infect Genet Evol.* 2017;47:56-63.
  50. Golovljova I, Vene S, Sjolander KB, Vasilenko V, Plyusnin A, Lundkvist A. Characterization of tick-borne encephalitis virus from Estonia. *J Med Virol.* 2004;74:580-8.
  51. Kozlova IV, Verkhzina MM, Demina TV, et al. Genetic and Biological Properties of Original TBEV Strains Group Circulating in Eastern Siberia. In: *Encephalitis.* Ed Tkachev S: InTech; 2013:95-112. doi: 10.5772/54087.
  52. Gritsun TS, Frolova TV, Pogodina VV, Lashkevich VA, Venugopal K, Gould EA. Nucleotide and deduced amino acid sequence of the envelope gene of the Vasilchenko strain of TBE virus; comparison with other flaviviruses. *Virus Res.* 1993;27:201-9.
  53. Gritsun TS, Frolova TV, Zhankov AI, et al. Characterization of a Siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. *J Virol.* 2003;77:25-36.
  54. Mavtchoutko V, Vene S, Haglund M, et al. Characterization of tick-borne encephalitis virus from Latvia. *J Med Virol.* 2000;60:216-22.
  55. Golovljova I, Katargina O, Gellera J, et al. Unique signature amino acid substitution in Baltic tick-borne encephalitis virus (TBEV) strains within the Siberian TBEV subtype. *Int J Med Microbiol.* 2008;298:108-20.



56. Tonteri E, Jaaskelainen AE, Tikkakoski T, et al. Tick-borne encephalitis virus in wild rodents in winter, Finland, 2008- 2009. *Emerg Infect Dis.* 2011;17:72-5.
57. Karan LS, Pogodina VV, Frolova TV, Platonov AY. Genetic diversity of East European and Asian strains of tick-borne encephalitis virus belonging to Siberian genotype. *Bull Siberian Med.* 2006;51:24-8.
58. Andaev EI, Sidorova EA, Borisova TI, et al. Tick-borne encephalitis in the Trans-Baikal region and molecular-biological characteristics of the pathogen. *National Priorities of Russia.* 2011;2:148-50.
59. Pogodina VV, Karan LS, Koliashnikova NM, et al. Polytypic strains in the gene pool of tick-borne encephalitis virus. *Vopr Virusol.* 2012;57:30-6.
60. Khasnatinov MA, Danchinova GA, Kulakova NV, et al. Genetic characteristics of the causative agent of tick-borne encephalitis in Mongolia. *Vopr Virusol.* 2010;55:27-32.
61. Ernek E, Kozuch O, Lichard M, Nosek J, Albrecht P. Experimental Infection of *Clethrionomys glareolus* and *Apodemus flavicollis* with Tick-Borne Encephalitis Virus. *Acta Virol.* 1963;7:434-6.
62. Kozuch O, Gresikova M, Nosek J, Lichard M, Sekeyova M. The role of small rodents and hedgehogs in a natural focus of tick-borne encephalitis. *Bull World Health Organ.* 1967;36 Suppl:61-6.
63. Radda A, Hofmann H, Pretzmann G. Threshold of viraemia in *Apodemus flavicollis* for infection of *Ixodes ricinus* with tick-borne encephalitis virus. *Acta Virol.* 1969;13:74-7.
64. Burri C, Korva M, Bastic V, Knap N, Avsic-Zupanc T, Gern L. Serological evidence of tick-borne encephalitis virus infection in rodents captured at four sites in Switzerland. *J Med Entomol.* 2012;49:436-9.
65. Achazi K, Ruzek D, Donoso-Mantke O, et al. Rodents as sentinels for the prevalence of tick-borne encephalitis virus. *Vector Borne Zoonotic Dis.* 2011;11:641-7.
66. Bardos V. Natural foci of neuro-infections in the Danube region. *Cesk Epidemiol Mikrobiol Imunol.* 1957;6:381-91.
67. Rieger M, Nübling M, Müller W, Hasselhorn H-M. Foxes as indicators for TBE endemicity – a comparative epidemiological investigation. *Zentralbl Bakteriol.* 1999;289:610-8.
68. Apitzsch L. Untersuchung über Reservoir der Zeckenezephalitis und ihre epidemiologische Bedeutung im Herdgebiet Torgelow. *Zeitschr Ges Hyg.* 1965;11:65-74.
69. Freundt EA. The Western boundary of endemic tick-borne meningoencephalitis in southern Scandinavia. *Acta Pathol Microbiol Scand.* 1963;144:87-103.
70. Labuda M, Eleckova E, Lockova M, A S. Tick-borne encephalitis virus foci in Slovakia. *Int J Med Microbiol.* 2002;291 suppl 33:43-7.
71. Kristiansen K. TBE in Denmark – in particular on Bornholm. *Int J Med Microbiol.* 2002;291 suppl. 33:62-3.
72. Vasilenko V, Golovljova I, Kutsar K, Jöggiste A, Plyusnin A, A L. TBE foci in Estonia. *Int J Med Microbiol.* 2002;291, suppl. 33:182.
73. Han X, Aho M, Vene S, et al. Studies on TBE epidemiology in Finland (and Lithuania). *Int J Med Microbiol.* 2002;291 suppl 33:48-9.
74. Juceviciene A, Vapalahti O, Laiskonis A, Ceplikiene J, P L. Prevalence of tick-borne encephalitis antibodies in Lithuania. *J Clin Virol.* 2002;25:23-7.
75. Skapaas T, Sundoy A, Bruu AL, et al. Tick-borne encephalitis in Norway. *Tidsskr Nor Laegeforen.* 2002;122:30-2.
76. Gresikova M, Calisher CH. Tick-borne encephalitis. In: *The Arboviruses: Epidemiology and Ecology.* Ed Monath TP. Boca Raton, Florida: CRC Press, Inc.; 1988:chapter 45, 177-202.
77. Matile H, Aeschlimann A, R W. Seroepidemiological investigations on the incidence of TBE in man and dog in Switzerland. In: *Tick-borne encephalitis.* Ed Kunz C: International Symposium Baden/Vienna 1979, Facultas Verlag Wien; 1979:227-34.
78. Satz N. *Frühsommer-Meningenzephalitis (FSME).* Bern, Switzerland: Verlag Hans Huber; 2006.
79. Collard M, Gut JP, Christmann D, et al. L'encephalite a tiques en Alsace. *Rev Neurol (Paris).* 1993;149:198-201.
80. Molnar E. Occurrence of tick-borne encephalitis and other arbovirus in Hungary. *Geogr Medica.* 1982;12:78-120.
81. Han X, Aho M, Vene S, Peltomaa M, Vaheri A, Vapalahti O. Prevalence of tick-borne encephalitis virus in ticks in Finland. *J Med Virol.* 2001;64:21-8.
82. Labuda M, Stützner D, Kozuch O, et al. Tick-borne encephalitis virus activity in Styria, Austria. *Acta virol.* 1993;37:187-90.
83. Gresikova M, Masar I. Epidemiology of tick-borne encephalitis (TBE) in Czecho-Slovakia. *Ellipse.* 1991;29:451-3.
84. Dai X, Shang G, Lu S, Yang J, Xu J. A new subtype of eastern tick-borne encephalitis virus discovered in Qinghai-Tibet Plateau, China. *Emerg Microb Infect.* 2018;7:74.
85. Klaus C, Beer M, Saier R, et.al. Goats and sheep as sentinels for tick-borne encephalitis (TBE) virus--epidemiological studies in areas endemic and non-endemic for TBE virus in Germany. *Ticks Tick Borne Dis.* 2012;3:27-37.